Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- Top Insights from The Scope Forward Show 2025
- Augmented Reality to Improve Ergonomics; Positive Stool Tests and Polyp Location (GI & Endoscopy News)
- Capsule Endoscopy (GI & Endoscopy News)
- Underused Method of Colorectal Endoscopic Submucosal Dissection Could Improve Outcomes (Medscape)
- OpenAI launches ChatGPT Health, partners with b.well (MobiHealthNews)
- Freenome Delivers Improved Performance in Its Colorectal Cancer Blood Test with Sensitivity of 85% for CRC and 22% for Advanced Precancerous Lesions (Freenome)
- Ro Launches Wegovy® Pill Through Integration with Novo Nordisk (Ro)
- The impact of the GI physician shortage (Becker’s GI & Endoscopy)
